Calder Douglas W 4

What Happened Douglas W. Calder, a director of Zevra Therapeutics (ZVRA), received a grant of options covering 30,000 shares on June 4, 2026. The Form 4 reports the award as a derivative acquisition with a reported amount of $0 (the filing shows no cash paid). The exercise price is set equal to Zevra’s closing common stock price on the Nasdaq Global Select Market on the grant date, so the option had no intrinsic value at grant if the market price equals the exercise price.

Key Details

• Transaction type: Grant / award of options (derivative), code A on Form 4.
• Grant date: 2026-06-04; Filing date: 2026-06-18 (filed more than 2 business days after the transaction).
• Amount: 30,000 option shares; reported consideration: $0.
• Exercise price: equals closing price of ZVRA common stock on 2026-06-04 (per footnote).
• Vesting: 100% vests on the earlier of (i) first anniversary of grant, (ii) the day before the first annual stockholders meeting after the grant, or (iii) immediately prior to a change in control, subject to continued service.
• Purpose: Awarded as non-employee director compensation under the company’s director compensation policy (per footnote).
• Shares owned after transaction: Not specified in the summary data provided in this request.

Context This is a standard director compensation grant, not a cash purchase or sale. Because the exercise price equals the market close on the grant date and vesting is delayed, the award does not represent an immediate monetary gain and is meant to align the director’s interests with shareholders over time. The filing was submitted on June 18 for a June 4 transaction, which is later than the typical Section 16 reporting window (2 business days) and may be noted by investors as a late filing.